Silexion Therapeutics CORP Form 4 insider transactions

Silexion Therapeutics Corp. officer Mitchell Shirvan reports acquisition of 6,000 ordinary shares via settled RSUs and provides updated derivative security ownership following a 1-for-10 reverse stock split.

Hadar Mirit Horenshtein, CFO and Secretary of Silexion Therapeutics Corp, was granted 7,500 ordinary shares via fully vested restricted stock units.

Ilan Hadar, Director and CEO of Silexion Therapeutics Corp, reported a grant of restricted share units settled into ordinary shares and provided updated beneficial ownership following a reverse stock split.

A fund associated with Silexion Therapeutics Corp director Shlomo Noy acquired ordinary shares and stock options for director services.

Silexion Therapeutics Corp director Ruth Alon was granted 9,091 ordinary shares and options to purchase 10,685 ordinary shares for her services.

Silexion Therapeutics' Chief Scientific and Development Officer, Mitchell Shirvan, reported the acquisition of 49,726 ordinary shares through an RSU grant, following two significant reverse share splits.

Silexion Therapeutics Corp's CFO and Secretary, Hadar Mirit Horenshtein, received a grant of 49,726 ordinary shares as compensation.

Silexion Therapeutics Corp's Chairman and CEO, Ilan Hadar, reported the acquisition of 64,350 ordinary shares through a restricted share unit grant, following two significant reverse stock splits.

Silexion Therapeutics Director Dror Yosef Abramov acquired 9,091 ordinary shares and 10,685 stock options through board-approved grants.

Silexion Therapeutics Corp director Amnon Peled received grants of 7,576 ordinary shares and 8,904 stock options, increasing his beneficial ownership.

Silexion Therapeutics Director Avner Lushi indirectly acquired 9,091 ordinary shares and 10,685 stock options through Guangzhou Sino-Israel Biotech Fund for director services.

Ilan Levin and Moringa Sponsor report changes in beneficial ownership of Silexion Therapeutics Corp, including a disputed share issuance and warrant adjustments following reverse stock splits.

Silexion Therapeutics Director Dror Yosef Abramov reported the grant of 794 ordinary shares as RSUs and 935 stock options, with all figures adjusted for recent reverse stock splits.

Silexion Therapeutics Director Ruth Alon reported the acquisition of 794 ordinary shares via RSU grant and 935 stock options, adjusted for recent reverse stock splits.

Silexion Therapeutics Director Shlomo Noy reported an acquisition of 1,587 ordinary shares and 1,872 stock options through indirect beneficial ownership via Guangzhou Sino-Israel Biotech Fund.

Silexion Therapeutics Corp director Avner Lushi indirectly acquired ordinary shares and stock options through Guangzhou Sino-Israel Biotech Fund, with holdings adjusted for recent reverse stock splits.

Silexion Therapeutics Director Amnon Peled acquired 661 ordinary shares and 780 stock options, with both awards vesting on February 9, 2026.

Biomotion Sciences is set to merge with Moringa Acquisition Corp, aiming to advance its siRNA platform technology targeting KRAS-driven cancers, with a focus on its lead candidate SIL-204.

Biomotion Sciences is set to go public via a merger with Moringa Acquisition Corp, aiming to advance its siRNA platform technology targeting KRAS-driven cancers, with promising clinical data from its lead candidate, SIL-204.